Oncobesity News Posts

The Information Survey: More Than Half of Respondents Take a GLP-1
It’s not exactly news that Ozempic, Wegovy and other GLP-1 drugs are catching on, with some surveys showing nearly 12% of Americans have used the

WHO adds weight-loss, diabetes drugs to essential medicines list
UN agency urges production of affordable generics for GLP-1 drugs to treat obesity and diabetes in developing countries.

WHO has added GLP-1 drugs to the essential medicines list. Here’s what that means
GLP-1 drugs were initially developed for diabetes, but have become wildly popular weight-loss drugs too

US FDA Sends Import Alert to Stop Illegal Imports of Obesity Drug Ingredients
(Reuters) -The U.S. Food and Drug Administration sent an import alert on Friday to help stop illegal imports of GLP-1 drug ingredients entering the…

FDA targets illegal imported GLP-1 ingredients
Post Content

Biomedicines, Vol. 13, Pages 2174: Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs
Biomedicines, Vol. 13, Pages 2174: Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs Biomedicines doi: 10.3390/biomedicines13092174 Authors:

WHO Adds GLP-1 Drugs for Diabetes, Others to Essential Medicines List
The World Health Organization has added GLP-1 drugs to treat diabetes to its essential medicines list alongside treatments for cystic fibrosis and cancer, and said

Trend tracker: Spotlight on China’s infant formula market, biotics, eye health
Find out more about recent trends in China’s infant formula sales, eye health supplement ingredients, and biotics for GLP-1 in this round-up.

The GLP-1 Effect: A New Path to Male Fertility?
Explore how GLP-1 therapies, beyond weight loss and diabetes care, may influence male fertility by improving hormonal balance, metabolism, and reproductive health outcomes.

GLP-1 Agonists Show Possible Benefits for Rare Blood Cancer
(MedPage Today) — HOUSTON — Patients with polycythemia vera (PV) and a history of treatment with GLP-1 agonists had significantly lower rates of multiple adverse

CVS Facing Lawsuit for Supporting Wegovy Over Other GLP-1s
CVS Health Corp.’s pharmacy benefit manager Caremark RX LLC is facing a lawsuit challenging its decision to stop coverage of weight loss drug Zepbound in

SupplySide Global 2025 to Spotlight Transformative Industry Trends in Artificial Intelligence, Natural Colors, GLP-1 Innovations and Global Trade Impacts – The Globe and Mail
SupplySide Global 2025 to Spotlight Transformative Industry Trends in Artificial Intelligence, Natural Colors, GLP-1 Innovations and Global Trade Impacts The Globe and Mail

Why GLP‑1 drugs should be covered beyond weight loss
When I turned 50, I weighed 265 pounds. Over the next 12 years, through walking, yoga, and strength training, I lost 60 pounds and kept

GLP-1 Use After Bariatric Surgery on the Rise
An increasing proportion of bariatric surgery patients are taking GLP-1 weight-loss drugs in the years following their surgery. Medscape Medical News

Weight-loss drug semaglutide shown to reduce cocaine use in rats
Scientists have found that the diabetes/weight loss drug semaglutide, sold commercially under brand names like Ozempic and Wegovy, significantly reduces cocaine-seeking behavior in rats. This work needs to be confirmed in humans, but it suggests that semaglutide is a candidate to be developed as a treatment for cocaine dependency; at the moment there is no effective pharmacological treatment for cocaine dependency.

MeAgain – Navigate your GLP-1 Journey
MeAgain is designed specifically for people on GLP-1 medications like Ozempic®, Wegovy®, Mounjaro®, Zepbound®, generics and compounds. MeAgain helps you build and stay on track

How Glucagon-Like Peptide-1 Medications Are Depicted in Instagram Posts Regarding Women’s Health, Nontraditional Access, and Barriers to Access: Content Analysis
Background: Glucagon-like peptide-1 (GLP-1) medications, recently introduced in the United States for treating type 2 diabetes and obesity, have sparked interest and discussion on social

As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off
After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her pharmacy benefit manager in April. Her

Starbucks hops on the health craze with protein coffee weight-loss influencers had been concocting in its drive thru for months
Starbucks is rolling out a protein-rich product line starting Sept. 29. Its new protein cold foam and protein lattes aim to capitalize on the growing

Why Is Inspire (INSP) Up 7.5% Since Last Earnings Report?
A month has gone by since the last earnings report for Inspire Medical Systems (INSP). Shares have added about 7.5% in that time frame, outperforming

14 Percent of U.S. Adults Initiate GLP-1 Receptor Agonist After Bariatric Surgery
WEDNESDAY, Sept. 3, 2025 — Fourteen percent of individuals initiate glucagon-like peptide 1 receptor agonists (GLP-1 RAs) after bariatric surgery, according to a study published

Cost Savings From GLP-1 Weight Loss Drugs Still Elusive
The study showed clinical benefits for semaglutide-based products used strictly in obesity care, but the model projects added net costs for their use in weight

Suicide and Self-Harm Events With GLP-1 Receptor Agonists
This systematic review and meta-analysis evaluates the risk of suicidality and self-harm in randomized, placebo-controlled trials of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in

Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines

Oral GLP-1 Pill For Weight Loss Shows Promise, But Challenges Remain
Experts see a place for pill formulations of GLP-1s as treatment for patients to switch to after reaching a target weight or blood sugar level

HIMS’ Personalized Wellness Platform Expands Preventive Care Access
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, positions itself as a consumer-first health and wellness platform, designed to transform the

Weight loss drugs protect heart patients, study suggests
Health Weight loss drugs protect heart patients, study suggests 40% lower risk of hospitalization or death Mass General Brigham Communications September 2, 2025 3 min

GLP-1s reduce heart failure death, hospitalization: 3 things to know
Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published

GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
TUESDAY, Sept. 2, 2025 — Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to

GLP-1 Drugs May Cut Dementia and Stroke Risk for Some Patients
For patients with type 2 diabetes (T2D) and obesity, glucagon-like peptide-1 (GLP-1) drugs may offer neuroprotective and cerebrovascular benefits in addition to glycemic control, a

I Am Taking a GLP-1 Weight-Loss Medication—What Should I Know?
This JAMA Internal Medicine Patient Page describes how glucagon-like peptide-1 (GLP-1) receptor agonists work and what behaviors to adopt while using them.

A GLP-1 Pill Is Coming to Shake Up the Weight Loss Drug Market
Eli Lilly is on track to release orforglipron next year, which has showed an average of 12 percent weight loss.

Reassessment of antibody-based detection of the murine T cell GLP-1 receptor
Glucagon-like peptide 1 receptor (GLP-1R) agonists exhibit anti-inflammatory actions, yet the importance of direct immune cell GLP-1R signaling remains uncertain. Although T cells respond to

Eli Lilly’s New Drugs Beyond Mounjaro and Zepbound Boost Sales
Eli Lilly and Company LLY has gained tremendous market value in the past 2-3 years due to the success of its popular GLP-1 drugs, Mounjaro

Unique and conserved endoplasmic reticulum stress responses in neuroendocrine cells
Endocrine cells are dedicated to the production and processing of hormones, from peptides to small molecules, to regulate key physiological processes, including glucose homeostasis and

Novo’s Wegovy Cuts Cardio Risk by 57% Versus Tirzepatide
Novo Nordisk’s Wegovy has been on a winning streak as of late, with a metabolic dysfunction-associated steatohepatitis approval last month and prime position in the oral obesity race.

Could GLP-1 weight-loss medications like Ozempic become the ‘everything drug’?
GLP-1 agonists — including semaglutides like Ozempic and Wegovy and tirzepatides like Mounjaro and Zepbound — were originally intended to treat type 2 diabetes and

Why Some of the Most Important Money in Tech Might Be About to Disappear
From GPS to GLP-1 drugs, game-changing ideas often start with federal research dollars funding wacky experiments. Slashing it risks the trillion-dollar industries of tomorrow.

Lilly ends 2 of 3 mid-stage trials for oral GLP-1 contender naperiglipron
As the oral GLP-1 race intensifies, Eli Lilly has slimmed back the number of phase 2 trials it is conducting for one of its contenders.

Novo Shares Gain As Wegovy Shows Big Edge Over Lilly’s Tirzepatide In Heart Study
Novo Shares Gain As Wegovy Shows Big Edge Over Lilly’s Tirzepatide In Heart Study Novo Nordisk shares rose in Copenhagen trading on Monday after the